Biotech News

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion Therapeutics (ESPR)Esperion Therapeutics2026-06-25 13:46 ESTClinical readout

– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial

Open original release

Related news

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

View all latest news

Esperion Therapeutics

Esperion Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ESPREsperion Therapeutics2026-06-26 12:03 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-06-26 12:03 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-06-26 12:03 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

ESPREsperion Therapeutics2026-06-26 12:03 EST

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

ESPREsperion Therapeutics2026-06-26 12:03 EST

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States